This survival benefit was associated with significantly increased CD45+ immune infiltrates, including CD4+ and CD8+ T cells, in S100a4−/− host gliomas (Fig. 6h–j, Supplementary Fig. 9e–i). This evidence concerns the gene CD8A and central nervous system cancer.